Wrocław-based biopharmaceutical company Biotts has filed a patent application for transdermal semaglutide and other GLP-1 molecules in the US and plans to launch the finished product by the end of 2026. According to Reuters, the market for semaglutide and similar drugs using GLP-1 analogues will reach $100 billion in annual sales this decade. The company […]
Read the full article